FibroBiologics, Inc. (FBLG)
NASDAQ: FBLG · Real-Time Price · USD
1.125
-0.115 (-9.27%)
At close: Feb 21, 2025, 4:00 PM
1.130
+0.005 (0.44%)
After-hours: Feb 21, 2025, 6:50 PM EST
FibroBiologics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
39.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionFBLG News
- 17 days ago - FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates - GlobeNewsWire
- 7 weeks ago - FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing - GlobeNewsWire
- 7 weeks ago - D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing - GlobeNewsWire
- 2 months ago - FibroBiologics Announces $25 Million Financing - GlobeNewsWire
- 3 months ago - FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly - GlobeNewsWire
- 3 months ago - FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics - GlobeNewsWire
- 3 months ago - FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology - GlobeNewsWire